Astera Labs (ALAB) files Form 144 for 33,000-share sale via Morgan Stanley
Rhea-AI Filing Summary
Astera Labs, Inc. (ALAB) filing a Form 144 notifies a proposed sale of 33,000 common shares through Morgan Stanley Smith Barney LLC on NASDAQ with an aggregate market value of $6,012,600.00. The shares were acquired 11/30/2018 in a private acquisition from the issuer and paid in cash. The filing lists multiple prior 10b5-1 sales by related trusts and entities between 06/20/2025 and 07/21/2025, including individual sales of 51,000, 58,000, 29,000 and others. The signer represents no undisclosed material adverse information and cites a Rule 10b5-1 trading plan context where applicable.
Positive
- None.
Negative
- None.
Insights
TL;DR: Notice of a planned 33,000-share sale by an insider-account holder; prior 10b5-1 executions show active disposals in June–July 2025.
The filing is a routine disclosure under Rule 144 showing a proposed sale of 33,000 shares valued at $6.01M, executed through Morgan Stanley Smith Barney LLC on NASDAQ. The securities were originally acquired in 2018 from the issuer in a private transaction and paid in cash, which supports their non-restricted provenance. Multiple 10b5-1 sales listed for related trusts and entities between 06/20/2025 and 07/21/2025 indicate ongoing liquidation activity by affiliated holders. For investors, this is informational rather than a company operational disclosure; materiality is limited to potential share supply into the market.
TL;DR: Proper Rule 144 notice filed; acquisition history and 10b5-1 disclosures are documented, with no disclosure of undisclosed material information.
The form provides the required representations under Rule 144, including the signer’s attestation they possess no undisclosed material adverse information. The record shows the securities were a private acquisition from the issuer on 11/30/2018, paid in cash, which typically satisfies the holding period and provenance tests for resale. The schedule of recent 10b5-1 sales for multiple related accounts is clearly reported, demonstrating compliance with prearranged trading plans. From a governance and disclosure perspective, the filing appears procedurally complete for the transaction described, with no statements beyond the required representations.
FAQ
What shares is ALAB planning to sell under this Form 144?
When were the shares being sold originally acquired?
Are there recent related sales reported in the filing for ALAB?
Who is the broker handling the proposed sale?
Does the filer state they possess any undisclosed material information?